Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 35-year-old woman with a history of limited cutaneous systemic sclerosis presents to the clinic complaining of worsening pain and episodic color changes in her fingers. When she is exposed to cold air, her digits turn distinctly white, then blue, and eventually red. She is currently not taking any medications for this specific symptom but wants to know how her condition will be managed if it continues to progress. Arrange the following interventions in the standard step-wise escalating sequence for the management of secondary Raynaud phenomenon, from initial conservative management to treatments reserved for severe, refractory digital ischemia.

  1. 1Implement cold avoidance, dress warmly, and ensure smoking cessation
  2. 2Initiate an oral dihydropyridine calcium channel blocker (e.g., nifedipine)
  3. 3Add a phosphodiesterase-5 inhibitor (e.g., sildenafil)
  4. 4Administer an intravenous prostanoid (e.g., epoprostenol)

Answer

The standard step-wise management of secondary Raynaud phenomenon begins with conservative lifestyle modifications, followed by oral calcium channel blockers as first-line pharmacotherapy. If symptoms persist, phosphodiesterase-5 inhibitors are added as second-line oral agents. Intravenous prostanoids are reserved for severe, refractory digital ischemia.
The correct sequence mirrors the standard clinical escalation for secondary Raynaud phenomenon, which balances therapeutic efficacy against the risk of adverse medication effects. Management universally starts with conservative lifestyle modifications. When pharmacologic intervention becomes necessary, oral dihydropyridine calcium channel blockers are the preferred first-line agents. For patients who remain symptomatic, second-line oral agents like phosphodiesterase-5 inhibitors are added. Highly potent, invasive therapies such as intravenous prostanoids are exclusively reserved as a last resort for severe, refractory digital ischemia complicated by impending tissue loss or active ulceration.

Step-by-Step Solution

1
Identify the clinical presentation and underlying condition.
The patient has secondary Raynaud phenomenon driven by limited cutaneous systemic sclerosis.
Establishing the severity and secondary nature of the vasospasm dictates the need for a formal, step-wise treatment algorithm.
2
Determine the initial, least invasive intervention.
Cold avoidance and smoking cessation.
Conservative lifestyle modifications carry no adverse medication effects and are universally indicated as the foundation of therapy.
3
Identify the first-line and second-line pharmacotherapies.
Oral calcium channel blockers, followed by phosphodiesterase-5 inhibitors.
Dihydropyridine calcium channel blockers are the most effective initial oral vasodilators. PDE-5 inhibitors are the preferred add-on agents if monotherapy fails.
4
Identify the treatment for severe, refractory cases.
Intravenous prostanoids.
Due to their invasive route of administration and side effect profile, these are strictly reserved for organ-threatening or digit-threatening ischemic crises.

Key Concept

Step-wise management of secondary Raynaud phenomenon
Estimated Time:1m 0s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic